Summary
PFE Chart
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Pfizer Inc. Dividends
 PFE 28 Jul 2022 | Other | $0.4 Per Share |
| PFE 12 May 2022 | Other | $0.4 Per Share |
| PFE 27 Jan 2022 | Other | $0.4 Per Share |
| PFE 4 Nov 2021 | Other | $0.39 Per Share |
| PFE 29 Jul 2021 | Other | $0.39 Per Share |
Pfizer Inc. Earnings
| 5 Aug 2025 (In 1 week) Date | | 0.57 Cons. EPS | - EPS |
| 28 Jul 2025 (In 5 days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
| 28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
| PFE 28 Jul 2022 | Other | $0.4 Per Share |
| PFE 12 May 2022 | Other | $0.4 Per Share |
| PFE 27 Jan 2022 | Other | $0.4 Per Share |
| PFE 4 Nov 2021 | Other | $0.39 Per Share |
| PFE 29 Jul 2021 | Other | $0.39 Per Share |
| 5 Aug 2025 (In 1 week) Date | | 0.57 Cons. EPS | - EPS |
| 28 Jul 2025 (In 5 days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
| 28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
Pfizer Inc. (PFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Pfizer Inc. ever had a stock split?
Pfizer Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Albert Bourla CEO | XSGO Exchange | US7170811035 ISIN |
| US Country | 81,000 Employees | 25 Jul 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Overview
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.
Products and Services
- Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
- Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
- Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
- Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
- Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
- Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
- Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
- Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.
Contact Information
